Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$0.67 USD
-0.03 (-4.41%)
Updated Jul 16, 2024 03:59 PM ET
After-Market: $0.68 +0.01 (1.19%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Brokerage Reports
Aptose Biosciences, Inc. [APTO]
Reports for Purchase
Showing records 21 - 40 ( 146 total )
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Halt of APTO-253 a Tough But Respectable Decision as Focus Shifts Entirely to Kinome Inhibitors; Target Adjusted to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
First Look at HM43239 Highlights a Quickly Advancing Portfolio of Kinase Inhibitors
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; We Believe Upcoming ASH Should Revitalize Shares; Target Increased to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
HM43239 Beefs Up a Growing Portfolio of Anti-Leukemic Assets
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Crunch Time Coming for Assets as Company Expands; Keep an Eye On
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Incremental Updates in Three Phase 1a/b Trials
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Luxeptinib Continues to Build a Promising Profile in Very Tough Populations at EHA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; Three Phase 1a/b Trials Advance; Comprehensive Update Expected at EHA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2020 Results; Dose Escalation in Luxeptinib Trials Continues; AML CR Excites with All Eyes on EHA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CG-806 ASH Update Continues Crawl Along; Leading Indicators Point to Likely Evolving Responses
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CG-806 Begins Treatment of r/r AML at Targeted Efficacious Dose; Key Updates Expected at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 results; ASH Can''t Get Here Fast Enough
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CG-806 Continues to Build a Promising Profile at EHA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; Blocking and Tackling Continues as Trials Expand
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Incremental AACR Data; Push for Responses Continues
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2019 Results; Anticipating the Switch From PK/PD to Responses Hopefully Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Our Take on CG-806''s Development in CLL: Addressing Therapy Resistance In Combination Regimens
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J